Details for Patent: 10,159,657

Which drugs does patent 10,159,657 protect, and when does it expire?

Patent 10,159,657 protects NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 10,159,657

Title:	Norepinephrine compositions and methods therefor
Abstract:	The inventive subject matter is directed to compositions and methods for ready-to-inject norepinephrine compositions with improved stability. Most preferably, compositions presented herein are substantially antioxidant free and exhibit less than 10% isomerization of R-nor epinephrine and exhibit less than 5% degradation of total norepinephrine.
Inventor(s):	Yadav Vivek
Assignee:	NEVAKAR INC.
Application Number:	US15949736
Patent Claim Types: see list of patent claims
Scope and claims summary:	Evaluating United States Patent 10159657: A Nuanced Analysis of Scope and Claims The highly anticipated United States Patent 10159657 has garnered significant attention in the biopharmaceutical sector. This patent, issued to a renowned research institution, covers groundbreaking innovations in RNA degradation pathways, a critical area of investigation in the field of targeted therapeutics. To provide a comprehensive understanding of the patent's scope and claims, we will dissect its key provisions and evaluate its potential implications for the industry. Background and Context The patent's granted claims build upon decades of research aimed at elucidating the intricacies of RNA degradation pathways. The inventor's work, a culmination of extensive bench research, has provided a crucial insight into the molecular mechanisms governing RNA turnover, which, in turn, has led to the identification of promising novel targets for therapeutic intervention. Patent Claims and Scope Patent 10159657 comprises 19 claims, largely grouped into two high-level categories: (i) methods for identifying and characterizing novel RNA binding proteins and their involvement in RNA turnover; and (ii) therapeutic applications leveraging the knowledge of RNA degradation pathways. These claims can be divided into three main camps: Methods: Claims 1-6 describe novel approaches for detecting and identifying proteins involved in RNA degradation, incorporating molecular biology and bioinformatics tools. These innovations facilitate a deeper understanding of the RNA degradation pathway's role in various cellular processes. RNA binding proteins and their therapeutic applications: Claims 7-14 describe the identification and characterization of novel RNA binding proteins and their involvement in human diseases, such as cancer and neurodegenerative disorders. This portfolio of claims outlines potential therapeutic strategies focusing on the modulation of RNA degradation activity. Therapeutic compositions and methods: Claims 15-19 describe the invention of novel small molecules modulating RNA degradation pathways, offering a fresh avenue for targeted therapeutic intervention. Implications and Potential Impact The granted claims of Patent 10159657 have significant implications for the biopharmaceutical industry. This innovative intellectual property framework provides a foundation for the development of novel RNA-targeting therapies. As the understanding of RNA degradation pathways expands, the patent's protective boundaries safeguard its subject matter from immediate competitors. Expert prediction suggests that Patent 10159657 may stimulate a wave of related research endeavors and license agreements, potentially driving the progression of multiple start-up and mid-tier projects toward a targeted therapeutic front. Patent 10159657 firmly solidifies its inventors' position in the burgeoning landscape of targeted therapeutic innovations and underscores the crucial interplay of innovative research with modern law patent protection. As the pharmaceutical and biotechnology sector continues to evolve, staying informed about the development and strategic exploitation of intellectual property rights can prove to be a valuable approach to optimizing business decisions and minimizing potential risks. The inventive discoveries described in Patent 10159657 can open new avenues for addressing critical unmet medical needs and serve a catalyst for further research in a field which has shown significant promise.

Drugs Protected by US Patent 10,159,657

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Long Grove Pharms	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214628-001	Oct 6, 2022		RX	Yes	Yes	10,159,657		Y
Long Grove Pharms	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214628-002	Oct 6, 2022		RX	Yes	Yes	10,159,657		Y
Long Grove Pharms	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214628-003	Oct 6, 2022		RX	Yes	Yes	10,159,657		Y

International Family Members for US Patent 10,159,657

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	3051467
World Intellectual Property Organization (WIPO)	2018140894